Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 11/20 | 0.41 |
| ▸ | TAB1 | Q15750 | 11/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16703716 | 0.95 | MAP3K7 (0.42) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL18045674 | 0.92 | MET (0.39) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16697681 | 0.92 | PTGDR2 (0.38) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16698457 | 0.91 | MET (0.45) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16697640 | 0.90 | MET (0.40) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16698267 | 0.90 | MET (0.39) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16697893 | 0.89 | MET (0.47) | MAP3K7TAB1METHTR6HTR2A | |
| SCHEMBL16697708 | 0.89 | MET (0.48) | MAP3K7TAB1METHTR6GSK3B | |
| SCHEMBL16697789 | 0.88 | MAP3K7 (0.49) | MAP3K7TAB1METHTR6 | |
| SCHEMBL16697918 | 0.87 | MET (0.40) | MAP3K7TAB1METHTR6GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-3066090-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067782-A1 | 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263087-A1 | NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, TPH1 | MAP3K7 2586/4885TAB1 2489/4885MET 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.